Mumbai: Wockhardt has announced that Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 percent clinical efficacy in treating seriously ill patients with infections caused by ...
Shares of Wockhardt were in high demand on Monday after the company said that its drug Zaynich has achieved over 97 per cent clinical efficacy in treating critically ill patients with ...
The current investigation aimed to evaluate the susceptibility of bacterial isolates from urinary tract infections (UTIs) to a variety of antibiotics, including ciprofloxacin, trimethoprim, amikacin, ...